Brief: Shanghai Henlius Biotech Inc Says Jinzhou Avanc Pharmaceutical To Grant Exclusive License
03/12/2025 14:41
Dec 3 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK: JINZHOU AVANC PHARMACEUTICAL TO GRANT EXCLUSIVE LICENSE TO COMMERCIALISE FOVINACICLIB CITRATE CAPSULES EXCLUSIVE LICENSE TO COMMERCIALISE FOVINACICLIB CITRATE CAPSULES IN MAINLAND CHINA Further company coverage: 2696.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln